Aramis Biotechnologies

Executive Summary

Aramis Biotechnologies is a privately held preclinical-stage company dedicated to developing novel gene therapies for rare genetic disorders, with a primary focus on central nervous system (CNS) and metabolic diseases. Founded in 2019 and headquartered in Research Triangle Park, North Carolina, the company leverages its expertise in gene therapy to address significant unmet medical needs in patient populations with limited or no treatment options. While still in the preclinical phase, Aramis has the potential to advance its pipeline toward clinical development, targeting conditions that often have strong genetic validation and clear regulatory pathways for rare diseases. The company's approach, which may involve adeno-associated virus (AAV) or other vector technologies, positions it within the competitive but rapidly evolving gene therapy landscape. As a private entity, Aramis Biotechnologies has not disclosed specific funding amounts or valuation, but its focus on severe genetic disorders could attract strategic partnerships or venture capital interest as it approaches key milestones.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program30% success
• Q4 2026Series A Financing Announcement50% success
• Q2 2026Preclinical Proof-of-Concept Data Release70% success